TrialDiabetes, obesity & metabolism2016

Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.

L Zang et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 368 people · 2016

Not counted

Probably lowered glycemic control

−0.67percentage points−0.86 to −0.48

As reported

difference −0.67 %, 95% CI −0.86 to −0.48

Not counted

Probably raised glycemic control

3.6×2.2× to 6.1×

Bigger than 8 in 10 for glycemic control

As reported

OR 3.65, 95% CI 2.18–6.12

Two numbers in the abstract

the abstract, start to end

… for liraglutide vs sitagliptin of -0.67% (95% CI -0.86, -0.48) or -7.35 …

… (53 mmol/mol) at week 26 [odds ratio 3.65 (95% CI 2.18, 6.12); p < …

← favours treatmentfavours comparator →

could be chance

Glycemic control

−0.67−0.86 to −0.48

Glycemic control

OR 3.652.18–6.12

GLP-1 receptor agonistsDPP-4 inhibitorsGlycemic control

1 / 3

22 papers cite it

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

this paperpooled ittrialcites it

The trial

NCT02008682phase 4368 enrolled2013